Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the ...

In May, the FDA approved GSK’s GSK RSV vaccine, Arexvy, forthe prevention of LRTD caused by RSV in older adults aged 60+ years. This was the first RSV vaccine for older adults to be approved ...

The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect ...

The European Medicines Agency (EMA) and the European Centre for Disease Control (ECDC) recommend targeting people at risk in ...

New Scientist explains how the latest covid-19 booster vaccines are different from previous ones, and who should get them ...

Updated COVID-19 vaccines are being rolled out in the U.S., aimed at targeting the latest, prevalent variants of the disease.

GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare ...

Pregnant people should get an RSV vaccine from Pfizer that transfers antibodies to their babies, according to a new CDC ...

In a nearly unanimous vote, advisors to the Centers for Disease Control and Prevention have recommended a new vaccine to ...

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60. Arexvy is a vaccine used for the prevention of respiratory syncytial ...

GSK plc (GSK, GSK.L) said Japan's Ministry of Health, Labour and Welfare has approved Arexvy for the prevention of respiratory ...

Pfizer PFE announced that the European Commission has approved its new vaccine, Abrysvo, for the prevention of respiratory syncytial virus (RSV) in infants through immunization of their pregnant ...